Welcome to our dedicated page for Attovia Therapeutics SEC filings (Ticker: ATTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Attovia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Attovia Therapeutics's regulatory disclosures and financial reporting.
venBio Global Strategic Fund IV, L.P., a 10% owner of Attovia Therapeutics, Inc., reported multiple equity transactions tied to Attovia’s initial public offering. On August 6, 2026, the fund converted 21,477,273 Series A, 7,636,362 Series B, and 6,179,219 Series C Preferred Stock shares into Common Stock as part of an automatic conversion at IPO, as adjusted for a 1-for-9.29 reverse stock split effective July 29, 2026. The filing also reports an additional open-market purchase of 382,352 Common Stock shares at $17.00 per share. These securities are held directly by venBio Global Strategic Fund IV, L.P.; its general partner entities and members disclaim beneficial ownership beyond their pecuniary interest.
Attovia Therapeutics, Inc. reported insider activity by investment entities associated with Redmile Group and Jeremy Green as ten percent owners. On August 6, 2026, 782,854 shares of Series B Preferred Stock automatically converted in full into the same number of common shares upon completion of Attovia’s IPO for no consideration. On the same date, Redmile-managed vehicles purchased an additional 600,000 shares of common stock at $17.00 per share in the IPO, including a 200,000-share direct purchase that brought one reported direct common position to 982,854 shares. The filing notes that Redmile and Jeremy Green may be deemed beneficial owners through their roles as manager and principal, while disclaiming beneficial ownership beyond any pecuniary interest.
Frazier Life Sciences XI, L.P., together with affiliated general partners FHMLS XI, L.P. and FHMLS XI, L.L.C., reported multiple conversions of preferred stock in Attovia Therapeutics, Inc. On August 6, 2026, Series A‑1, A‑2, B and C Preferred Stock automatically converted into Common Stock on a 9.29:1 basis immediately upon closing of Attovia’s initial public offering, eliminating these preferred positions. In connection with these automatic conversions, Frazier received blocks of Attovia Common Stock, all held directly by Frazier Life Sciences XI, L.P. In a separate transaction the same day, Frazier purchased 588,235 shares of Attovia Common Stock at $17.00 per share in an open‑market or private transaction, increasing its Common Stock holdings; post‑transaction Common Stock balances are not specified in this report.
Attovia Therapeutics director Angie You received a grant of stock options for 27,000 shares of common stock. The options have an exercise price of $17.00 per share and expire on August 3, 2036. According to the terms, the options vest in full on the earlier of August 4, 2027 or the next annual stockholders’ meeting, subject to continued service. Following this grant, the reported derivative holdings from this award total 27,000 options held directly.
Attovia Therapeutics, Inc. reported that director Mitchell Gold received a grant of 27,000 stock options to buy common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the award terms, 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service.
Attovia Therapeutics’ Chief Business Officer, Zaneta Odrowaz, received a grant of stock options for 140,000 shares of common stock on August 4, 2026. The options carry a $17.00 per share exercise price and expire on August 3, 2036. 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, she holds 140,000 stock options directly.
Attovia Therapeutics, Inc. reported that Chief Scientific Officer Petter Veiby received a grant of stock options covering 140,000 shares of common stock at an exercise price of $17.00 per share. The options expire on August 3, 2036 and vest 25% on August 4, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, subject to continued service. Following this award, Veiby holds options on 140,000 shares directly.
Attovia Therapeutics, Inc. reported that Chief Medical Officer Chen Hubert received a grant of stock options covering 140,000 shares of common stock on August 4, 2026. The options have an exercise price of $17.00 per share and expire on August 3, 2036. Following this grant, Hubert holds 140,000 options directly. According to the vesting terms, 25% of the options vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the subsequent 36 months, subject to continued service.
Attovia Therapeutics, Inc. reported a grant of stock options to its Chief Financial Officer. The grant covers 140,000 Stock Options (Right to Buy) with an exercise price of $17.00 per share, expiring on August 3, 2036, and represents 140,000 options held after the transaction. The options relate to an equivalent number of shares of common stock.
According to the vesting terms, 25% of the options will vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, contingent on continued service to the company.
Attovia Therapeutics, Inc. reported a grant of stock options covering 538,300 shares of common stock with an exercise price of $17.00 per share. The options expire on August 3, 2036. According to the vesting schedule, 25% vests on August 4, 2027, with the remainder vesting in equal monthly installments over the following 36 months, subject to continued service.